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Abstract 
Purpose: Being the leading cause of liver disease and hepatocellular carcinoma, the hepatitis C virus (HCV) has become a growing 
public health threat within the United States. Of those individuals infected with human immunodeficiency virus (HIV), approximately 
25% are co- infected with HCV. Establishment of a hepatitis C collaborative drug therapy management (CDTM) service can expand 
the role of pharmacists in an interdisciplinary team improving health outcomes for an underserved HIV/HCV co-infected patient 
population.  
Summary: In 2016, physicians and pharmacists identified a need to establish Hepatitis C pharmacy services in an HIV clinic. Through 
the recent establishment of CDTM and implementation of pharmacy services, pharmacists are now given the autonomy to manage 
patients co-infected with HIV/HCV. It is believed that the addition of a clinical pharmacist to an interdisciplinary team will lead to 
improved SVR rates, adherence, and clinic revenue, as well as decreased ADRs and drug-drug interactions among co-infected 
patients.  
Conclusion: Implementation of HCV pharmacy services directed towards HIV/HCV co- infection is an essential patient-centered 
strategy addressing complex medication-related problems in an attempt to achieve optimal therapeutic outcomes. A single-centered, 
prospective study to evaluate HCV pharmacy services at the Treatment for Life Center clinic is currently ongoing. 
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Key Points 
1. Hepatitis C is a growing public health crisis that 
requires an interdisciplinary patient-centered 
approach to care. 
2. Clinical pharmacists are uniquely positioned to assist in 
the management of HCV patients, specifically in 
promoting preventative measures, providing 
education to improve medication adherence, assisting 
in initiating HCV therapy, managing drug-drug 
interactions and adverse events, monitoring treatment 
responses, and facilitating medication acquisition.  
3. The true role of pharmacists in assisting in the 
management of chronic disease states, such as HCV, is 
brought to its true potential through the 
establishment of collaborative drug therapy 
management. 
 
 
Corresponding author: Maria A. Sorbera, PharmD, AAHIVP, 
BCACP, Assistant Professor of Pharmacy Practice  
Arnold & Marie Schwartz College of Pharmacy and Health 
Sciences Long Island University 
Brooklyn, New York 11201 
Ambulatory Care Faculty Preceptor, The Brookdale Hospital 
Medical Center, Brooklyn, NY 11212  
E-mail: maria.sorbera@liu.edu 
 
Background 
Often referred to as the “silent epidemic,” the hepatitis C virus 
(HCV) has emerged as a major public health crisis in the United 
States. It is suspected that there are, at present, up to 9 
million people in the country both acutely and chronically 
infected with HCV. Approximately 75 to 85% of acutely 
infected patients advance to chronic infection leading to 
possible complications of cirrhosis and/or hepatocellular 
carcinoma.1 HCV-related mortality is expected to rise and peak 
somewhere between 2030 and 2035, with an estimated 
36,100 deaths.2 With treatment factored in, this mortality rate 
is likely to be lower. These statistics emphasize the need for 
increased HCV screening efforts among healthcare 
professionals and institutions as well as improved transitions 
into care. Considering that about one quarter of HIV-infected 
individuals are also infected with HCV, it is essential for HIV 
providers to be knowledgeable in the management of both 
disease states.3 Co-infection with HIV accelerates liver disease 
progression warranting the need for prompt screening and 
treatment of HCV.4  
 
The treatment of chronic HCV has undergone an evolution in 
the last few years with the development of direct-acting 
antivirals (DAAs). Compared to former interferon (IFN) and 
ribavirin (RBV) based regimens, DAAs are oral treatment 
options that when used in recommended combinations are 
associated with improved efficacy and tolerance with 
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decreased durations of therapy. Results of clinical trials 
suggest that these regimens routinely achieve a cure, defined 
as a sustained virologic response 12 weeks post treatment 
(SVR12), in ≥90% of individuals including those who are 
treatment experienced and/or cirrhotic.5 The development of 
this novel class of medications finally allows healthcare 
providers to effectively combat the silent epidemic of HCV. 
However, this fight does not come without a steep cost. 
 
In comparison to former HCV therapies, DAAs are associated 
with greater wholesale acquisition costs ranging from $650 to 
$1,125 per day of therapy.6,7   The actual price paid by the 
patient may be significantly lower due to third party contracts, 
manufacturer rebates, and discounts.  Additionally, the 
process of acquiring third-party prior authorization approvals 
for DAAs can potentially delay treatment. Healthcare 
professionals involved with the treatment of HCV must stay 
up-to-date with the different requirements and restrictions of 
various insurance plans. Along with medication approvals, 
ongoing education within clinics and institutions is essential in 
order for providers to stay abreast the present and rapidly 
evolving treatment regimens. 
 
With the newly approved DAAs, healthcare is not at a paucity 
of HCV treatment options. As DAAs are all efficacious with 
similar cure rates when used in recommended combinations, 
the determining factors when selecting a regimen are patient-
specific. Providers and pharmacists must take into account 
differences in drug pharmacokinetics and dynamics, as well as 
potential clinically significant drug-drug interactions (CSDDIs). 
In an interdisciplinary setting, pharmacists are able to assist in 
initiating HCV therapy, manage CSDDIs and adverse events, 
monitor treatment responses, facilitate medication 
acquisition, promote preventative measures to reduce HCV 
transmission and re-infection, and provide education to 
improve medication adherence. This role is brought to its true 
potential through the establishment of collaborative drug 
therapy management (CDTM) increasing the autonomy of the 
pharmacist. 
 
The involvement of pharmacists in anticoagulation services, 
HIV care, cystic fibrosis, and diabetes has been shown to 
increase adherence, reduce pill burden and dosing frequency, 
and decrease medication-related errors.8 Johnson and 
colleagues found that pharmacists can reduce drug-related 
morbidity and mortality for 28.2% of hospital admissions with 
an estimated savings of $76.6 billion in an ambulatory setting.9 
In a pilot study retrospectively evaluating outcomes from 
2002-2004 in a pharmacist-managed HCV clinic at the Los 
Angeles Department of Veterans Affairs (VA) Healthcare 
System, it was concluded 17 out of 27 enrolled patients (63%) 
achieved SVR.10 During the time of this pilot study, DAAs were 
not yet approved. Therefore, the lower SVR rates achieved 
were similar to the real-world cure rates of older regimens. In 
2017, Yang and colleagues assessed the economic and clinical 
outcomes of pharmacy-led HCV utilization management in a 
VA Medical Center. In this retrospective study, a total of 372 
patients were included in which the majority received 
ledipasvir/sofosbuvir or ombitasvir/paritaprevir/ritonavir with 
dasabuvir ± ribavirin. Overall, the SVR rate achieved was 
94.1%. Investigators concluded the findings were suggestive 
that pharmacist-led HCV DAA utilization management is an 
important factor in costs and cure rates.11 Although research 
in this field is limited, the role clinical pharmacists can play to 
assist in improving patient-directed care includes education 
and counseling, managing drug-drug interactions, monitoring 
for efficacy and toxicities, and assisting in providing affordable 
medications to patients. 
 
The initiation of CDTM services through a collaborative 
practice agreement (CPA) between pharmacists and health 
care providers in an HIV/HCV infected population can offer 
great benefits in both hospital and patient-centered health 
outcomes. Legalized in New York State in 2011, CDTM is 
currently limited to teaching and general hospitals, including 
any diagnostic center, treatment center or hospital-based 
outpatient department.12 
 
Brookdale Hospital and Medical Center (BHMC) is a 530-bed 
tertiary care treatment facility with more than 50 specialty 
clinics including the Treatment for Life Center (TLC). 
Designated as a New York State (NYS) AIDS Center in 1993, the 
clinic provides a wide range of services to approximately 750 
patients including HIV testing and counseling, treatment and 
partner notification, case management, as well as pharmacy, 
laboratory and social work services. Located in East New York, 
Brooklyn, the TLC cares for a highly underserved patient 
population. The incidence of HIV in Brooklyn is 6% lower than 
the incidence for New York City as a whole; however, wide 
disparities exist within the borough. East New York has been 
identified as a neighborhood that has one of the highest 
incidences of HIV and HIV/AIDS with lower rates of viral 
suppression.13,14  
 
To aid in increasing viral suppression rates and improve 
treatment outcomes for other chronic disease states, the TLC 
utilizes an interdisciplinary approach to patient care. With the 
emergence of DAAs, the clinic developed a need for HCV 
services. As a direct response to this need, pharmacy 
established an HCV clinic with the goal to achieve high SVR 
rates and decrease HCV- associated morbidity and mortality 
within this medically underserved community. This article will 
describe the implementation process of hepatitis C pharmacy 
services through a CPA at the TLC. 
 
Implementation of Hepatitis C Pharmacy Services 
Prior to the establishment of a CPA, the primary model for 
pharmacy services at the TLC was a walk-in medication 
adherence clinic in which scheduled appointments were not 
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often made. Providers referred patients to the clinic who were 
identified as non-adherent, and these patients were often 
enrolled in pill tray services. On average, 120-180 patients 
were enrolled in these services. As HIV, along with several 
other chronic disease states were managed in the TLC, 
patients would be on multiple medications placing them at an 
increased risk for non-adherence and medication-related 
adverse events. On a regular basis, the clinic ambulatory care 
pharmacist conducted extensive chart reviews in order to 
identify medication interventions. However, without a formal 
agreement, interventions were dependent on follow-up time 
with the physicians due to the pharmacists’ lack of autonomy. 
Allowing clinical pharmacists to provide a comprehensive 
medication management service optimized through a CPA was 
proposed, particularly in managing those co-infected with 
HCV. 
 
To prepare for the development of a CPA, the pharmacists in 
the TLC attended professional development activities aimed at 
establishing and sustaining ambulatory care clinics, and 
consulted various healthcare professionals who practice under 
CDTM to obtain their professional guidance. Informal and 
formal verbal discussions occurred between the clinical 
pharmacists and BHMC physicians to ensure internal needs 
were mutually understood between both parties. The needs of 
the clinic expressed by providers included medication 
counseling and management specifically for the co-infected 
population.  Discussions also took place with administrators, 
nurse practitioners, social workers and patient navigators, and 
the agreement included all noted suggestions. For 3 months, 
the pharmacy department held several meetings to review and 
edit drafts. 
 
In January 2016, a final CPA draft was completed and approved 
by pharmacy. Following this, a meeting was held with all clinic 
providers to present the agreement and privileges to be 
granted. The importance of the agreement was unanimous, 
and proceeding minor edits, was accepted by the TLC 
physicians, administration, the institution’s Legal Department, 
the Medical Executive Committee, and the Chief Medical 
Officer. Through the approval by all parties, the TLC CPA was 
the first formal practice agreement at the BHMC implementing 
CDTM and providing significantly greater autonomy to 
pharmacists. 
 
The approved CPA established a documented policy for 
medication management with a scope exceeding beyond HCV 
management. Other disease states in the protocol include HIV 
and related co-infections, asthma, COPD, diabetes, heart 
failure, hypertension, hyperlipidemia, and nicotine 
dependence. Prescribers may refer patients for other disease 
states and services outside of those specifically listed, such as 
therapeutic drug monitoring. For all referred patients under 
the CPA, pharmacists may initiate, modify, discontinue and 
refill medications, order and evaluate laboratory tests, obtain 
vital signs, and collect and review patient histories. Within 24 
hours of a patient care encounter, the pharmacist is required to 
communicate all treatment plans via the electronic medical 
record (EMR), which is then co-signed by the overseeing 
physician. The managing clinical pharmacists of these 
encounters are board-certified in ambulatory care and received 
their CDTM certification. Future pharmacists practicing under 
CDTM in the TLC will be required to have or have plans to 
obtain their board and CDTM certifications. 
 
Clinic Operation 
Patients are referred to HCV pharmacy services by their TLC 
physician if they are 18 years or older and are anticipated to 
start HCV treatment. Enrolled patients are then assigned an 
ambulatory care clinical pharmacist who will consistently 
follow the patient to ensure continuity of care. To standardize 
the care that is delivered to each patient, the clinic 
pharmacists utilize the Pharmacists’ Patient Care Process         
(Fig. 1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Pharmacists’ Patient Care Process: A standardized 
process that aims to promote consistency across the profession 
and assist in achieving optimal health and medication-related 
outcomes. Released by the Joint Commission of Pharmacy 
Practitioners (JCPP). The Pharmacists’ Patient Care Process 
JCPP. https://jcpp.net/patient-care-process/. Accessed 
September 17, 2017. 
 
Prior to the initial visit, the pharmacist accesses BHMC’s EMR, 
EPICTM, to review the patient’s medical history, co-morbid 
conditions, laboratory tests, and to perform medication 
reconciliation.  During the extensive review, pertinent 
information to HCV is gathered, including genotype, HCV RNA 
viral loads, stage of fibrosis and/or cirrhosis, and treatment 
history. Any further laboratory data that is warranted will be 
ordered and assessed by the pharmacist. Once all necessary 
information is obtained, the possible treatment options for 
the patient are determined in preparation for the initial visit. 
These options are communicated with the enrolled patient’s 
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TLC physician and a collaborative decision is made for the 
most appropriate regimen. 
 
At the initial patient encounter, written consent is obtained 
from the patient stating he/she would like to receive HCV 
treatment through pharmacy services. Education is provided on 
the disease state, treatment options, and most importantly, on 
adherence. It is critical that the patient’s readiness for 
treatment and ability to adhere to medication regimens is 
assessed prior to initiating therapy. The purpose of this 
assessment is not to deny treatment, but rather identify 
barriers and optimize support.  Within the TLC, potential 
barriers that may exist include the complexity of the 
medication regimens, polypharmacy, patient-provider 
relationships, and patient-specific factors. The NYC Hep C Task 
Force developed an online tool, The Psychosocial Readiness 
Evaluation and Preparation for Hepatitis C Treatment (PREP-C), 
which thoroughly assesses the patient’s psychosocial readiness 
to begin treatment and provides a plan to improve readiness. 
In conjunction with PREP-C, clinics can consider patient follow-
up phone calls, increasing the frequency of appointments, and 
establishing support groups promoting community and patient 
engagement. 
 
When discussing adherence and HCV treatment, one disease 
state that often is subject to controversy is drug abuse. 
Intravenous drug use (IVDU) is the primary mode of 
transmission for HCV, and is commonly seen as a factor that 
reduces adherence resulting in providers limiting access to 
treatment. By having a well-established relationship with the 
patient, the healthcare professional can assess the patient as a 
whole, rather than focusing in on one disease state.   
Literature has displayed evidence that patients who inject 
drugs have demonstrated adherence to prescribed 
HCVregimens.15 In studies containing treatment with IFN, 
adherence and efficacy rates were comparable to those who 
did not inject drugs. Considering the ease of administration, 
improved tolerability, and decreased duration of therapy, it 
can be hypothesized that DAAs may result in even greater 
adherence rates among IVDU populations in comparison to 
historic therapies. Within the TLC, drug abuse is not a hard 
stop to treatment. It merely serves as an indicator for the 
clinical pharmacist to further assess and determine if 
treatment is the best option at the current moment. 
Regardless of HCV treatment, all active drug users 
encountered are counseled and offered assistance in obtaining 
help. 
 
In addition to counseling to improve patient adherence and 
engagement, pharmacy services provide two standardized 
medication management forms, a personalized medication 
record (PMR) and a medication action plan (MAP) adapted 
from the Centers for Medicare and Medicaid Services (CMS). 
These forms are intended to assist patients in achieving 
treatment goals. The PMR allows the patient to maintain an 
update-to-date list of all current medications. Each patient is 
instructed to carry their PMR with them especially when going 
to different providers and/or hospitals. Along with the PMR, 
the MAP is a document mutually agreed upon by the 
pharmacist and patient that list actions for the patient to take 
in order to track their progress. At the completion of the first 
encounter, detailed schedules of all follow-up appointment 
times are discussed with and given to the patients.   It is the 
sole responsibility of the pharmacist to facilitate medication 
acquisition through the completion of prior authorizations, 
schedule follow-up encounters and/or phone calls, and order 
and assess necessary laboratory work. 
 
Follow-up 
Generally, HCV RNA viral loads are obtained on treatment 
weeks 4 and 12, and 12 weeks post- treatment. Aside from 
HCV RNA levels at treatment week 4, a complete blood count 
(CBC), creatinine level, and hepatic panel are ordered. Patients 
are notified of their laboratory results as soon as available in 
EPIC™.  Periodic follow-up phone calls are performed to 
remind patients of upcoming appointments, provide further 
adherence counseling, and assess CSDDIs and treatment 
tolerability. Additional visits may be required if unresolved 
medication-related problems arise or increased monitoring is 
necessary. 
 
Clinic discussions with the pharmacist and physician regarding 
treatment discontinuation occur with every patient who has a 
detectable HCV RNA level at treatment week 4. Repeat testing 
on treatment week 6 is usually recommended. As there is no 
clinic policy or protocol for patients with detectable viral loads, 
each is discussed on a case-by-case basis. Typically, if the HCV 
RNA level increases by greater than 10-fold on repeat testing, 
the HCV regimen will be discontinued. 
 
Challenges 
As expected, the development of HCV pharmacy services 
comes with its share of certain challenges. Many of the 
HIV/HCV co-infected patients are considered inactive, which is 
defined by the clinic as a patient who has not been seen within 
the last year. Attempts to reintegrate patients into care can 
become quite problematic. Contact information listed in the 
EMR is often out-of-date and cannot be utilized to locate 
patients. In the circumstance where a patient cannot be 
reached, the clinic will try to call emergency contacts. 
Extensive efforts to follow-up with inactive patients are 
necessary in order to avoid lapses in treatment, disease 
progression, and further HIV and HCV viral transmission. Once 
re-integrated, patients must be retained in care, which often 
presents as an even greater challenge. Empowering patients 
and giving them ownership of their own health is paramount 
in having successful retention rates. Rather than the 
traditional reactive healthcare model, patient-centered 
models should be utilized placing greater emphasis on 
provider-patient relationships. Patients must be involved in 
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their care plans, and understand the importance of adherence 
to medications, especially ARVs. One way pharmacists can 
motivate patients to play a more active role in their health is 
through education. 
 
The relationship existing between socioeconomic status and 
health literacy cannot go unacknowledged. Utilizing lay 
language when providing patient education on disease states 
in conjunction with the teach-back method is crucial.16,17 To 
ensure effective counseling and assess patient understanding, 
pharmacists should always ask patients to repeat a point of 
the counseling session back to them. Commonly in the TLC, 
lengthier counseling sessions with more frequent follow-up 
visits are necessary to increase patient disease state 
knowledge, clinic engagement, and medication adherence. 
However, the additional time required by the pharmacist to 
perform extensive counseling and follow-up places a higher 
demand for resources and pharmacy staff support. 
 
In addition to the increase in staffing demands, finding 
physician champions has been critical to the development and 
integration of our services. Despite the involvement of 
pharmacy services prior to CDTM, clinical pharmacists 
continue to provide physician education within the institution 
to discuss the role of the pharmacist in assisting to improve 
patient outcomes and potentially increase clinic revenue. 
 
As pharmacists broaden their roles in patient-centered care, 
we anticipate sustainability to be an ongoing challenge. 
Recognition by payers is a key component in sustaining clinical 
services. Although compensation for pharmacy services can be 
limited, it is the role of the clinical pharmacist to develop a 
continuing knowledge of CDTM practice billing in order to 
reduce errors and maintain appropriate levels of 
reimbursement for provided services.18,19  Presently, the clinic 
is not actively billing for pharmacist ambulatory care services. 
Majority of the pharmacy visits are done collaboratively with 
the physician during the medical visit. For clinic revenue 
purposes, it is not preferred for a pharmacist to see and bill 
patients on the same day as the physician largely due to CMS 
paying the lesser of the two bills rather than both claims.20 
Separate clinic days for pharmacy visits are in development 
with the addition of pharmacist incident-to billing. 
 
Future Directions 
Currently, the pharmacists in the TLC are conducting a single-
centered, prospective study to evaluate the newly established 
HCV pharmacy services. In 2015, the clinic treated 22 patients 
prior to the establishment of CDTM in which 19 patients 
achieved SVR12 (86%). Treatment response rates from the 
study population will be compared to clinic rates in 2015. 
Secondary outcomes that will be evaluated include avoidable 
drug-drug interactions, adherence, care cost/revenue, 
reported ADRs, and SVR rates according to genotype and stage 
of fibrosis/cirrhosis. Through the implementation of HCV 
pharmacy services, we propose that the addition of a clinical 
pharmacist to an interdisciplinary team treating HIV/HCV co-
infected patients will lead to improved SVR rates, decreased 
medication-related ADRs, and increased adherence, number 
of drug-drug interactions avoided, and clinic revenue. 
 
As expansion of services to primary care clinics and increased 
clinic recruitment from hospitalized patients occurs, it is 
anticipated that there may be some hesitation from providers 
in referring patients. Education and advertisement of pharmacy 
clinic services will be developed to potentially curb any 
uncertainty. In-services to both inpatient and outpatient teams 
and presentations at medical grand rounds are planned along 
with interprofessional continuing education lectures. Although 
there will be a large focus on institutional education, it is the 
hopes of the clinic to extend its educational efforts to the 
community. 
 
Many opportunities exist for community outreach in the East 
New York area given the patient population. As such, the TLC 
pharmacists plan to provide community educational sessions to 
aid in reducing the risk of viral transmission and increase 
screening rates. Of course, this cannot be a one-time session. 
The medical presence in the community must be sustained in 
order to build patient-provider relationships and maintain an 
ongoing trend of education and trust. As the TLC evolves, we 
hope to leave our mark in the East New York community by 
serving as public health advocates for this silent epidemic. 
 
Conclusion 
Implementation of HCV pharmacy services for those co-
infected with HIV requires a patient- centered strategy in order 
to address medication-related problems among this unique 
patient population. Integrating pharmacists into 
interdisciplinary teams through the establishment of CDTM 
provides an extra source of support for patients potentially 
increasing the quality of care received. It is the clinic’s belief 
that the addition of HCV pharmacy services will allow for 
improved SVR and adherence rates. As the burden of HCV-
related morbidity and mortality continues to increase, clinical 
pharmacists can rise to the challenge of fighting the silent 
epidemic by becoming integral members of the medical teams 
and providing comprehensive medication management 
services through the development of CPAs. 
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